Q-omics provides the consensus-scored GPR108 profile across patient tissues and cancer cell-line models. GPR108 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPR108 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, GPR108 protein abundance shows 20,931 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, LIHC, and PDAC as cancer lineages where GPR108 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR108 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR108 survival associations across molecular data types. GPR108 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR108 RNA expression–survival associations across cancer types. High GPR108 expression shows unfavorable associations in UVM, UCS and LGG, but favorable associations in KIRC, UCEC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPR108 RNA expression.
This table summarizes GPR108 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GPR108. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR108 shows lower tumor expression in KICH, LUSC, UCEC and LUAD and higher tumor expression in LIHC and KIRC. The LIHC box plot shows higher GPR108 RNA expression in tumor versus normal tissue (log2 FC = +1.116, t-test p < 0.001).
This table shows molecular features associated with GPR108 in patient tissues and cancer cell lines. In patient samples, GPR108 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR108 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
